Mannosylated nanoparticulate carriers of rifabutin for alveolar targeting

References

• Agashe HB, Dutta T, Garg M, Jain NK. (2006). Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J Pharm Pharmacol, 58, 1491–1498.
   PubMed Web of Science ®Google Scholar
• Agrawal P, Gupta U, Jain NK. (2007). Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials, 28, 3349–3359.
   PubMed Web of Science ®Google Scholar
• Alexandra D, Raymond JJ, Frederick W van G, Romy F, Angela T, Stephen HL, Kohtaro F, Hiroshi K, McGhee Jerry R, Prosper NB. (2006). Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens. J Immunol, 176, 1776–1783.
   PubMed Web of Science ®Google Scholar
• Bala I, Hariharan S, Kumar MN. (2004). PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst, 21, 387–422.
   PubMed Web of Science ®Google Scholar
• Barluenga J, Aznar F, Garcıa A, Cabal M, Palacios J, Menendez M. (2006). New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Bioorg Med Chem Lett, 16, 5717–5722.
   PubMed Web of Science ®Google Scholar
• Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, Korvick JA, Heifets L, Child CC, Lederman MM, Reichman RC, Powderly WG, Notario GF, Wynne BA, Hafner R. (2000). Clarithromycin or RFB alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS. J Infect Dis, 181, 1289–1297.
   PubMed Web of Science ®Google Scholar
• Bhadra D, Bhadra S, Jain S, Jain NK. (2003). A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm, 257, 111–124.
   PubMed Web of Science ®Google Scholar
• Bhadra D, Bhadra S, Jain NK. (2005). PEGylated peptide-based dendritic nanoparticle systems for delivery of artemther. J Drug Deliv Sci Technol, 15, 65–73.
   Web of Science ®Google Scholar
• Curvo SL, Luısa T, Caseiro AF. (2005). Tuberculosis of the chest. Eur J Radiol, 55, 158–172.
   PubMed Web of Science ®Google Scholar
• Davis BG, Robinson MA. (2002). Drug delivery systems based on sugar macromolecule conjugates. Curr Opin Drug Discov Dev, 5, 279–288.
   PubMed Web of Science ®Google Scholar
• Duncan R, Dimitrijevic S, Eyagororou EG. (1996). The role of polymer conjugate in the diagnosis and treatment of cancer. STP Pharm Sci, 6, 237–263.
   Google Scholar
• Garnett MC, Stolnik S, Dunn SE, Armstrong I, Lin W, Schacht E, Ferutti P, Vert M, Davies MC, Ilium L. (1999). Application of novel biomaterials in colloidal drug delivery systems. RS Bull, 24, 49–56.
   Google Scholar
• Gaspar MM, Cruz A, Penha AF, Reymão J, Sousa AC, Eleuterio CV, Domingues SA, Fraga AG, Longatto FA, Cruz MEM, Pedrosa J. (2008). Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int J Antimicrob Agents, 31(1), 37–45.
   PubMed Web of Science ®Google Scholar
• Gelperina S, Kisich K, Iseman MD, Heifets L. (2005). The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med, 172, 1487–1490.
   PubMed Web of Science ®Google Scholar
• Grassi C, Peona V. (1996). Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis, 22(1), S50–S54.
   PubMedGoogle Scholar
• Iseman MD. (2002). Tuberculosis therapy: past, present and future. Eur Respir J, 20, 87S–94S.
   Web of Science ®Google Scholar
• Kumar PV, Asthana A, Dutta T, Jain NK. (2006). Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers. J Drug Target, 14(8), 1–11.
   PubMed Web of Science ®Google Scholar
• Kumar PV, Agashe H, Dutta T, Jain NK. (2007). PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Curr Drug Del, 4, 1–9.
   PubMedGoogle Scholar
• Li J, Munsiff SS, Driver CR, Sackoff J. (2005). Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997–2000. Clin Infect Dis, 41, 83–91.
   PubMed Web of Science ®Google Scholar
• Maclean D, Toulouse B. (1997). Rifabutin (Mycobutin), CATIE Fact Sheet. http://www.catie.ca.
   Google Scholar
• Muller RH, Wallis KH. (1993). Surface modification of i.v. injectable biodegradable nanoparticles with poloxamer polymers and poloxamine 908. Int J Pharm, 89, 25.
   Web of Science ®Google Scholar
• Muller RH, Mehnert W, Lucks JS, Schwarz C, Zur Muhlen A, Weyhers H, Freitas C, Ruhl D. (1995). Solid lipid nanoparticles (SLN)—an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm, 41, 62.
   Web of Science ®Google Scholar
• O’Brien RJ, Lyle MA, Zinder DE. (1987). Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis, 9, 519–530.
   PubMedGoogle Scholar
• Onyebujoh P, Zumla A, Ribeiro I, Rustomjee R, Mwaba P, Gomes M, Grange JM. (2005). Treatment of tuberculosis: present status and future prospects. Bull World Health Organ, 83, 857–865.
   PubMed Web of Science ®Google Scholar
• Peter DO. (1999). Multi-drug resistant tuberculosis. http://priory.com/chest.htm.
   Google Scholar
• Saito H, Sato K, Tomioka H. (1988). Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle, 69, 187–92.
   PubMedGoogle Scholar
• Schubert MA, Muller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles—evaluation of the method and process parameters. Eur J Pharm Biopharm, 55, 125–131.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma S, Khuller GK. (2004). Lectin-functionalized poly(lactideco-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother, 54, 761–766.
   PubMed Web of Science ®Google Scholar
• Siegal FP. (1996). Rifabutin prophylaxis for Mycobacterium avium complex infection in patients with AIDS. Clin Infect Dis, 22(1), S23–32.
   Google Scholar
• Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. (2001). Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release, 70, 1–20.
   PubMed Web of Science ®Google Scholar
• Stahl K, Claesson M, Lilliehorn P, Linden H, Backstrom K. (2002). The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm, 233, 227–237.
   PubMed Web of Science ®Google Scholar
• Starke Jeffrey R. (1997). Prevention of tuberculosis infection and disease. Sem Pediatr Infect Dis, 8(2), 85–95.
   Google Scholar
• Tomofumi U, Xin W, Katsuaki S, Misako H, Takami A, Mitsuru A, Masanori B. (2007). Targeting of antigen to dendritic cells with poly(γ-glutamic acid) nanoparticles induces antigen specific humoral and cellular immunity. J Immun, 178, 2979–2986.
   PubMed Web of Science ®Google Scholar
• Verma RK, Kaur J, Kumar K, Yadav AB, Misra A. (2008). Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob Agents Chemother, 52(9), 3195–3201.
   PubMed Web of Science ®Google Scholar
• Veronese FM, Calicetti P, Pastorino A, Schiavon O, Sartore L. (1989). Preparation, physicochemical and pharmacokinetic characterization of methoxy polyethylene glycol derivatized superoxide dismutase. J Control Release, 10, 145–154.
   Web of Science ®Google Scholar
• Vyas SP, Khar RK. (2002). Targeted and Controlled Drug Delivery Novel Carrier Systems (pp. 331–386 ). 1st ed. Delhi: CBS publishers and Distributors.
   Google Scholar
• Zur Muhlen, Schwarz C, Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur J Pharm Biopharm, 45, 149.
   PubMed Web of Science ®Google Scholar